Complexo Hospitalario Universitario de Santiago
Centro de atención
University of Leicester
Leicester, Reino UnidoPublicacións en colaboración con investigadores/as de University of Leicester (22)
2023
-
(Pre)treatment risk factors for late fatigue and fatigue trajectories following radiotherapy for breast cancer
International Journal of Cancer, Vol. 153, Núm. 9, pp. 1579-1591
-
Genome-wide association study of treatment-related toxicity two years following radiotherapy for breast cancer
Radiotherapy and Oncology, Vol. 187
-
Large-scale meta-genome-wide association study reveals common genetic factors linked to radiation-induced acute toxicities across cancer types
JNCI Cancer Spectrum, Vol. 7, Núm. 6
-
Reply to: Comments on “(Pre)treatment risk factors for late fatigue and fatigue trajectories following radiotherapy for breast cancer”
International Journal of Cancer
2022
-
Development and Optimization of a Machine-Learning Prediction Model for Acute Desquamation After Breast Radiation Therapy in the Multicenter REQUITE Cohort
Advances in Radiation Oncology, Vol. 7, Núm. 3
-
Efficacy of empagliflozin in heart failure with preserved versus mid-range ejection fraction: a pre-specified analysis of EMPEROR-Preserved
Nature Medicine, Vol. 28, Núm. 12, pp. 2512-2520
-
Mapping genomic loci implicates genes and synaptic biology in schizophrenia
Nature, Vol. 604, Núm. 7906, pp. 502-508
-
The correlation between pre-treatment symptoms, acute and late toxicity and patient-reported health-related quality of life in non-small cell lung cancer patients: Results of the REQUITE study: Symptoms, toxicity and quality of life of lung cancer patients
Radiotherapy and Oncology, Vol. 176, pp. 127-137
-
Treatment time and circadian genotype interact to influence radiotherapy side-effects. A prospective European validation study using the REQUITE cohort
eBioMedicine, Vol. 84
-
Use of angiotensin converting enzyme inhibitors is associated with reduced risk of late bladder toxicity following radiotherapy for prostate cancer
Radiotherapy and Oncology, Vol. 168, pp. 75-82
2021
-
Empagliflozin in heart failure with a preserved ejection fraction
New England Journal of Medicine, Vol. 385, Núm. 16, pp. 1451-1461
2019
-
REQUITE: A prospective multicentre cohort study of patients undergoing radiotherapy for breast, lung or prostate cancer
Radiotherapy and Oncology, Vol. 138, pp. 59-67
2018
-
Recommendations from the United European Gastroenterology evidence-based guidelines for the diagnosis and therapy of chronic pancreatitis
Pancreatology, Vol. 18, Núm. 8, pp. 847-854
2016
-
Distinct phosphorylation sites on the ghrelin receptor, GHSR1a, establish a code that determines the functions of ß-arrestins
Scientific Reports, Vol. 6
-
Oxaliplatin and 5-FU/folinic acid (modified FOLFOX6) with or without aflibercept in first-line treatment of patients with metastatic colorectal cancer: The AFFIRM study
Annals of Oncology, Vol. 27, Núm. 7, pp. 1273-1279
-
Prognostic significance of anaemia in patients with heart failure with preserved and reduced ejection fraction: Results from the MAGGIC individual patient data meta-analysis
QJM, Vol. 109, Núm. 6, pp. 377-382
2014
-
Genetic association study of QT interval highlights role for calcium signaling pathways in myocardial repolarization
Nature Genetics, Vol. 46, Núm. 8, pp. 826-836
2012
-
Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990-2010: A systematic analysis for the Global Burden of Disease Study 2010
The Lancet, Vol. 380, Núm. 9859, pp. 2197-2223
-
Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010: A systematic analysis for the Global Burden of Disease Study 2010
The Lancet, Vol. 380, Núm. 9859, pp. 2163-2196